Superseded public profile

Not FDA-approved↗Safety records↗

Superseded · version 1: Selank↗↗

Related names recorded in this version: Selank acetate↗

A synthetic seven-amino-acid peptide that FDA lists among withdrawn compounding nominations with possible safety risks. FDA states that it lacks important information on its safety in people.↗↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.

What this version reported

No human study is cited in the reviewed sources; the published work cited here is in rats. No FDA approval is reported, and selank is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗

Organizations named in cited records:
  • U.S. Food and Drug Administration↗↗
  • U.S. Department of Health and Human Services↗

Reader guide in this version

Key takeaway

Selank is a synthetic seven-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro), recorded in FDA’s substance registry and also known as TP-7.1,3 FDA lists selank acetate among compounding nominations that were withdrawn after FDA identified possible safety risks, and states that it lacks important information on its safety in people.3 No FDA approval is reported in the sources reviewed here, and selank is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.3,5

At a glance

What it is
A synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, according to FDA’s substance registry.1
FDA status
No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page lists selank acetate among withdrawn nominations with possible safety risks.3
Human evidence
None in the sources reviewed here. FDA states that it lacks important information on selank’s safety in people; the published work cited here is in animals.2,3
Evidence strength
Animal and lab studies only

What is selank?

Selank is a synthetic peptide of seven amino acids: threonine, lysine, proline, arginine, proline, glycine and proline. FDA’s substance registry records it as selank and TP 7.1

FDA’s compounding safety-risk page refers to it as selank acetate (TP-7).3

How is selank thought to work?

The authors of a 2017 rat study describe selank as an anxiety-reducing peptide whose action may resemble that of benzodiazepine drugs.2

That proposed mechanism comes from animal research; the FDA sources reviewed here do not describe how selank acts in people.2,3

What do human studies show?

No human study of selank is cited among the sources reviewed here. FDA states that it lacks important information regarding any safety issues raised by selank acetate given to humans.3

In a 2017 study in rats under chronic mild stress, selank alone and selank combined with diazepam reduced anxiety-like behaviour in an elevated maze test.2

What the evidence base contains

  • Animal or laboratory research A 2017 rat study reporting that selank reduced anxiety-like behaviour in a maze test, alone and combined with diazepam, under chronic mild stress.2

Evidence-strength label: Animal and lab studies only. How this label is assigned

Is selank FDA-approved?

None of the sources reviewed here reports an approval of selank by FDA.1,3

FDA’s compounding safety-risk page, current as of April 22, 2026, lists selank acetate among bulk drug substances that were in category 2 before their nominations were withdrawn, citing possible immune reactions from aggregation and impurities.3

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Selank is not among them.4,5

Timeline

  1. A rat study of selank under chronic mild stress is published.2
  2. FDA’s compounding safety-risk page, as last updated, lists selank acetate among withdrawn nominations with possible safety risks.3

What is still unknown?

Whether it is safe or effective in people: FDA states that it lacks important safety information, and no human study is cited here.3

Whether effects seen in rats would carry over to people.2

Sources for this version

  1. 1
    Selank substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  2. 2
    Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats (2017) · PMID 28280289 ↗

    Behavioural Neurology · Official source · Source checked November 15, 2026

  3. 3
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026